Article
Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
Journal of the National Cancer Institute - 7 Sept 1994
Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu W J, Takahashi R, Sugiyama T, Yoshida O
Abstract excerpt
BACKGROUND: Previously, p53 (also known as TP53) gene mutations have been shown to be frequently detected in highly malignant urothelial cancers. Evidence has been accumulating that the disruption of the normal function of p53 may lead to genomic instability, including predisposition to gene amplification. Furthermore, the normal function of p53 may be abrogated by MDM2 (murine double minute-2) gene amplification...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.